Showing results (1-10 of 39) with videos related to
Sort By:
Pageof 4
Nature Reviews. Cancer|July 25, 2006
Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitorsAlexander J Muller, Peggy A ScherleExpert Opinion on Investigational Drugs|July 12, 2011
Development of c-MET pathway inhibitorsXiangdong Liu, Robert C Newton, Peggy A ScherleTrends in Molecular Medicine|December 25, 2009
Developing c-MET pathway inhibitors for cancer therapy: progress and challengesXiangdong Liu, Robert C Newton, Peggy A ScherleExpert Opinion on Investigational Drugs|June 14, 2008
Targeting the c-MET signaling pathway for cancer therapyXiangdong Liu, Wenqing Yao, Robert C Newton, et al.Bioorganic & Medicinal Chemistry Letters|March 27, 2003
A new synthesis of cytoxazone and its diastereomers provides key initial SAR informationPercy H Carter, Jacob R LaPorte, Peggy A Scherle, et al.Arthritis and Rheumatism|January 16, 2003
Induction of aggrecanase 1 (ADAM-TS4) by interleukin-1 occurs through activation of constitutively produced proteinMichael A Pratta, Peggy A Scherle, Gengjie Yang, et al.Journal for Immunotherapy of Cancer|May 16, 2014
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironmentStefani Spranger, Holly K Koblish, Brendan Horton, et al.Expert Opinion on Investigational Drugs|July 12, 2005
ADAM proteases, ErbB pathways and cancerBin-Bing S Zhou, Jordan S Fridman, Xiangdong Liu, et al.Obesity (Silver Spring, Md.)|January 30, 2010
Insulin-induced ectodomain shedding of heparin-binding epidermal growth factor-like growth factor in adipocytes in vitroTakanobu Yamamoto, Takayoshi Suganami, Minako Kiso-Narita, et al.Journal of Clinical Pharmacology|June 27, 2014
The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteersJack G Shi, Xuejun Chen, Fiona Lee, et al.Pageof 4